Nuvaira kündigt Vortrag zur Bedeutung der zielgerichteten Lungendenervierung bei der Behandlung von COPD auf dem Internationalen Kongress der ERS an PARIS, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Nuvaira, ein Unternehmen, das medizinische Geräte zur Behandlung von obstruktiven Lungenkrankheiten entwickelt, hat heute die Annahme eines klinischen...

Nuvaira annonce un exposé oral lors du congrès international de l’ERS pour discuter de l’importance de la dénervation ciblée du poumon afin de traiter la BPCO PARIS, 18 sept. 2018 (GLOBE NEWSWIRE) -- Nuvaira, un développeur de dispositifs médicaux pour traiter les maladies pulmonaires obstructives, a annoncé aujourd’hui l’acceptation par la European...

Nuvaira Announces Oral Presentation at ERS International Congress Discussing Significance of Targeted Lung Denervation to Treat COPD PARIS, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Nuvaira, a developer of medical devices to treat obstructive lung diseases, announced the acceptance of a clinical abstract by the European Respiratory...

Nuvaira Announces 1st Patient Treated in RELIEF-1 Study Evaluating New Approach for Asthma Treatment MINNEAPOLIS, March 27, 2018 (GLOBE NEWSWIRE) -- Nuvaira, a developer of medical devices to treat obstructive lung diseases, today announced treatment of the first patient in the RELIEF-1 Clinical...

Nuvaira Announces Enrollment Completion in First Sham-Controlled Clinical Trial of Targeted Lung Denervation for COPD MINNEAPOLIS, June 27, 2017 (GLOBE NEWSWIRE) -- Nuvaira (formerly known as Holaira), a developer of medical devices to treat obstructive lung diseases, today announced completion of patient...